Poor Sleep, Daytime Sleepiness May Lead To Dementia: Read Details Here

Updated Dec 19, 2024 | 08:00 PM IST

SummaryLatest research has established a potential link between poor sleep and the development of dementia, particularly a condition called motoric cognitive risk syndrome (MCR).
Daytime Sleepiness

Daytime Sleepiness (Credit: Canva)

Experiencing daytime sleepiness is something that is usually perceived as a minor inconvenience, but for older adults, it could be an early warning sign of Dementia. This neurodegenerative disease leads to the progressive decline of brain cells. This eventually

affects memory, cognition, and personality, making everyday tasks more difficult. As one of the fastest-growing neurological disorders across the world, dementia poses a significant health threat to ageing populations.

Is Dementia Linked To Poor Sleep?

Daytime sleepiness is a direct result of poor sleep quality. Now, a recent research, published in the journal Neurology, highlighted a potential link between poor sleep and the development of dementia, particularly a condition called motoric cognitive risk syndrome (MCR). The study found that 35.5% of participants who reported extreme daytime sleepiness developed MCR, which is a precursor to dementia.

For this study, researchers followed 445 older adults (average age 76) over three years, aiming to determine whether poor sleep could increase the risk of mild cognitive impairment (MCI), which often leads to dementia. At the start, none of the participants had MCI, but by the end of the study, 36 individuals had developed the condition.

The researchers discovered that participants with poor sleep were more likely to develop MCI compared to those who slept well. However, when depression symptoms were taken into account, the link between poor sleep and MCI became less pronounced, suggesting that while sleep issues are a concern, mental health also plays a key role in dementia risk.

To assess sleep quality, the Pittsburgh Sleep Quality Index (PSQI) was used, evaluating factors such as sleep duration, disturbances, and daytime alertness. Among these, "daytime dysfunction"—defined as excessive sleepiness and low energy during the day—was most strongly associated with an increased risk of MCI. Those experiencing daytime dysfunction were more than three times as likely to develop MCI as those who didn’t report such symptoms.

There are many types of dementia:

Dementia is not a specific disease. According to the Centers for Disease Control and Prevention (CDC), it is an overall term that describes a decline in mental ability that interferes with daily life. People with dementia often have symptoms like trouble remembering, thinking, or making everyday decisions. These symptoms tend to get worse over time.

Alzheimer’s disease is the most common type of dementia, and it mostly affects the elderly. Each form of dementia has a different cause. Though dementia mostly affects older adults, it is not a part of normal ageing. An estimated 6.7 million older adults have Alzheimer's disease in the United States. That number is expected to double by 2060, as per data from the CDC.

In 2022, 3.8% of men and 4.2% women in US were diagnosed with dementia. The percentage of people increase with age from 1.7% for those aged 65-74 to 13.1% for those aged 85 and older. Alzheimer's accounts for 60 to 80% of all dementia cases and it is most prevalent in California, Florida, and Texas, as these states have the highest number of people.

End of Article

L'Oréal Settles Hair Relaxer Cancer Cases In First US Trial: Can Chemical Hair Straighteners Cause Cancer?

Updated Nov 17, 2026 | 09:27 AM IST

SummaryL'Oréal USA and several of its subsidiaries recently settled lawsuits related to their chemical hair relaxers and cancer risk in a trial held in Chicago,
L'Oréal Settles Hair Relaxer Cancer Cases In First US Trial: Can Chemical Hair Straighteners Cause Cancer?

Credit: AI-generated image

L'Oréal USA and other manufacturers of chemical hair relaxers have reached a settlement with four women who alleged that years of using hair straightening products contributed to their gynaecological cancers.

The settlement was made during the first US trial involving these claims, bringing newfound attention to research examining the health risks of chemical hair treatments.

What Do We Know About The L'Oréal's US Lawsuit?

According to Reuters, the four women, MaryAnne Lindsey, Surenthia Jenkins, Miranda Lofton and Sandra Simpson, settled their lawsuits for an undisclosed amount. The trial was being held in Chicago.

The women had sued L'Oréal's US subsidiary and several other manufacturers in 2023 and 2024, alleging that prolonged exposure to chemical hair straighteners caused their cancers.

The settlement comes as litigation involving these products continues to surface. More than 12,700 related cases have been consolidated before a federal judge in Chicago.

The products, sold under brand names including Dark and Lovely and Optimum, have been widely marketed to Black women.

Also read: What Is Viral Heightmaxxing? US Doctors Warn Teen Boys Against Taking Cancer Drug To Grow Taller

L'Oréal's Statement

L'Oréal has maintained that its products are safe. A company spokesperson said, "L’Oréal USA strictly follows all regulations in every market in which it operates and its products are always subject to a rigorous scientific evaluation of their safety."

The company has also argued that existing research does not establish that its products caused the conditions alleged in the lawsuits.

What Does Research Say About Hair Relaxers And Cancer?

Scientific interest in the health effects of chemical hair straighteners increased after a 2022 study by researchers at the US National Institutes of Health (NIH).

Published in the Journal of the National Cancer Institute, the study examined data from 33,497 women aged 35-74 participating in the Sister Study.

Over an average follow-up of nearly 11 years, 378 cases of uterine cancer were identified.

Researchers found that women who reported using chemical hair straightening products more than four times in the preceding year had more than twice the risk of developing uterine cancer compared to women who had never used them.

The study estimated that 1.64% of women who had never used hair straighteners would develop uterine cancer by age 70, compared to 4.05% among frequent users.

However, researchers did not focus on the specific brands or chemical ingredients used, meaning they could not identify which substances might have contributed to the observed association.

Also read: Can A 'Sponge On A String' Test Help Detect Oesophageal Cancer Before Symptoms?

High Risk Of Breast And Ovarian Cancer

Other studies have also investigated links between chemical hair treatments and reproductive cancers.

A 2021 study published in Carcinogenesis found that frequent use of hair straighteners and relaxers may cause an increased risk of ovarian cancer. Women who used these products more than four times a year had approximately twice the risk compared with non-users.

Research from the Sister Study cohort has also showed an increased risk of breast cancer due to frequent hair straightener use especially among women who used the products regularly.

However, the findings are not the same across all studies. A 2025 systematic review examining evidence among Black women in the US concluded that the epidemiological evidence that is available did not support an increased risk of breast, ovarian or uterine cancers due to hair relaxer use.

Are Chemicals In Hair Straighteners Dangerous For Health?

Chemical hair relaxers and straighteners contain different substances depending on their formulation. Some products may contain endocrine-disrupting chemicals, including phthalates and parabens, which can interfere with hormonal activity.

Other concerning chemicals include formaldehyde and certain preservatives. Some straightening treatments can release formaldehyde, a recognised carcinogen.

Researchers have suggested that exposure to endocrine-disrupting chemicals could affect hormonal tissues.

End of Article

Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Updated Nov 17, 2026 | 08:46 AM IST

SummaryThe European Commission granted marketing authorisation to Revolution Medicines to produce and sell RASONQUE (daraxonrasib) to treat aggressive metastatic pancreatic adenocarcinoma.
Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Credit: AI-generated image

The European Commission has approved RASONQUE (daraxonrasib), a targeted cancer medicine developed by Revolution Medicines, for patients with metastatic pancreatic adenocarcinoma.

The approval marks a milestone in advanced pancreatic cancer treatment, offering an alternative to chemotherapy, especially for patients whose cancer has progressed despite earlier treatment.

RASONQUE is an oral medication which is taken once daily. It is the first broad RAS-targeted medicine approved in Europe for metastatic pancreatic cancer and can be used in patients with or without an identified RAS tumour mutation.

The approval applies to all European Union member states and the European Economic Area countries Iceland, Norway and Liechtenstein. It does not extend to the UK or Switzerland, which have separate regulatory approval processes.

More About RASONQUE

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, is driven by alterations in the RAS genes. These genes produce proteins that are involved in regulating cell growth. When mutations keep RAS proteins active, they can drive uncontrolled cancer cell growth.

Around 147,000 people are diagnosed with pancreatic cancer in Europe each year. The five-year survival rate is also below 10%. As early-stage pancreatic cancer shows few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread.

Daraxonrasib works by blocking RAS proteins, which can become overactive in cancer cells and send signals that tell them to grow and multiply. It binds to a protein called cyclophilin A to form a complex that attaches to these active RAS proteins, preventing them from sending growth signals. This helps stop the cancer cells from growing and spreading.

Unlike treatments that target a single RAS mutation, daraxonrasib inhibits multiple RAS variants.

Also read: Bowel, Pancreatic & Liver: NHS Trial Offers New Blood Test To 20,000 Patients That Could Detect 13 Cancers

What Did The Clinical Trial Find?

The European Commission's decision was based on results from the Phase 3 RASolute 302 trial, which compared daraxonrasib with standard chemotherapy in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. Approximately 92% of participants had confirmed RAS G12 mutations.

According to the European Medicines Agency (EMA), patients receiving daraxonrasib had a median overall survival of 12.4 months, compared to 6.7 months among those receiving chemotherapy.

Median progression-free survival, which measures how long patients live without their disease worsening, was 7.2 months with daraxonrasib versus 3.6 months with chemotherapy.

The US Food and Drug Administration (FDA), which approved the drug in August 2026, also reported improvements in overall survival and progression-free survival in both patients with RAS G12 mutations and the overall trial population.

Also read: New Pancreatic Cancer Vaccine Triggers Immune Response In 99% Of Patients

What Are The Side Effects?

The most commonly reported side effects of daraxonrasib include diarrhoea, skin rash, stomatitis (inflammation of the mouth lining), nausea and vomiting.

The drug also carries warnings for serious complications like severe skin and soft tissue reactions, gastrointestinal perforation and interstitial lung disease or pneumonitis.

Although the European Commission has granted approval, patient access will depend on individual countries completing their pricing, health technology assessment and reimbursement processes.

Revolution Medicines said it is working with healthcare systems and relevant stakeholders across Europe to enable access to the treatment.

The approval follows an expedited assessment under the EMA's Cancer Medicines Pathfinder project, which aims to accelerate the evaluation of promising medicines addressing significant unmet medical needs.

End of Article

Popular Blood Pressure Medicine Propranolol Recalled In The US Over Possible Metal Contamination

Updated Nov 17, 2026 | 07:24 AM IST

SummaryPropranolol Hydrochloride Extended-Release Capsules, USP 60 mg, manufactured by Adare Pharma Solutions, were recalled voluntarily in the US due to concerns that it may contain metal particles.
Popular Blood Pressure Medicine Propranolol Recalled In The US Over Possible Metal Contamination

Credit: AI-generated image

Breckenridge Pharmaceutical, Inc. has announced a voluntary nationwide recall of a batch of Propranolol Hydrochloride Extended-Release Capsules, USP 60 mg in the US over concerns that the medication may contain metal particles.

The recall, announced on November 16, 2026, covers one lot of the blood pressure medication manufactured by Adare Pharma Solutions. The company initiated the recall after identifying a possible contamination linked to an intermediate material used in the affected batch.

According to the company's recall notice, the contaminated material was suspected to be the source of metal contamination identified in a separate lot that was not released into the market.

Risk Of Injuries To The Digestive Tract

The company has warned that taking capsules from the affected lot could cause physical injuries to soft tissues in the body.

According to the recall notice, use of the affected product could cause "lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine."

However, Breckenridge Pharmaceutical stated that it was not aware of any adverse events related to the recall at the time of the announcement.

The affected products were distributed to wholesalers and pharmacies across the US between October 26 and November 4, 2026.

Also read: From 4 To 100 Kratom Capsules A Day: Woman Shares Warning Signs Of Addiction

Which Propranolol Batch Has Been Recalled?

The recall is limited to a specific batch of 60 mg Propranolol Hydrochloride Extended-Release Capsules. The details are:

  • Product: Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg
  • Package size: 100-count bottle
  • NDC number: 51991-817-01
  • Affected lot number: PK25110035
  • Expiry date: May 2029

Those who have been prescribed the pill between the dates mentioned above are advised to check the product packaging and lot number to determine whether their medication is part of the recall.

Also read: Popular Anti-Anxiety Capsules Recalled Over Salmonella Fears: What Should Patients Know

What Should Patients Do?

Breckenridge Pharmaceutical has advised consumers to immediately stop taking the medication from the affected lot and contact their physician or healthcare provider for medical advice for obtaining a replacement.

"Consumers should return any unused portion of the affected product to the pharmacy where it was obtained," the company's announcement said.

Patients should also return any unused capsules from the recalled batch to the pharmacy where they purchased the medication. Anyone who has experienced health problems that could be due to the recalled medicine should contact their healthcare provider.

Pharmacies, wholesalers and other retailers have been instructed to check their inventories, quarantine the affected products and stop distributing or dispensing them.

Consumers seeking additional information about the recall can contact Qualanex, the company's designated recall service provider, at 1-855-736-0807 or email recall@qualanex.com. The recall is being conducted with the knowledge of the US Food and Drug Administration (FDA).

Also read: US FDA Recalls Thousands Of Blood Pressure Drugs Over Excess Drug Levels, Failed Quality Tests

What Is Propranolol Used For?

Propranolol belongs to a class of medicines called beta-blockers. It works by reducing the effects of certain stress hormones on the heart, thereby slowing the heart rate and reducing blood pressure.

The medication is commonly prescribed to manage high blood pressure and other cardiovascular conditions. It is also used for certain heart rhythm disorders, angina and migraine prevention.

The extended-release formulation is designed to release the medicine gradually over time, allowing effects that last long.

Propranolol's recall is the latest in a series of recent blood pressure medication recalls, including a recent one involving Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide tablets. They were recalled as they did not dissolve properly. A while go, Chlorthalidone tablets were also recalled for the same reason.

End of Article